Prices delayed by at least 15 minutes | Print
AB SCIENCE (AB)
AB SCIENCEThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
Address
Forecast key dates
Name | Key Date |
---|---|
AB Science Annual Report for 2024 | 2025-04-30T18:30:00 |
AB Science Second Quarter Earnings Results for 2024 | 2024-09-30T00:00:00 |
AB Science Annual General Meeting for 2023 | 2024-06-28T15:30:00 |
Previous key dates
Name | Key Date |
---|---|
AB Science Annual Report for 2023 | 2024-04-30T18:30:00 |
AB Science will host a live webcast | 2024-03-04T18:30:00 |
AB Science Second Quarter Earnings Results for 2023 | 2023-09-30T00:00:00 |
AB Science Annual General Meeting for 2022 | 2023-06-30T15:30:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.